Pediatric preclinical testing consortium evaluation of the EZH2 inhibitor tazemetostat in orthotopic PDX models of pediatric brain tumors.

被引：1
|
作者：
Li, Xiao-Nan
Qi, Lin
Kogiso, Mari
Lindsay, Holly Brianne
Erickson, Stephen W.
Guo, Yuelong
Smith, Malcolm A.
Teicher, Beverly A.
机构：
[1] Baylor Coll Med, Program Preclin Neuro Oncol Res, Texas Childrens Canc Ctr, Lab Mol Neuro Oncol, Houston, TX 77030 USA
[2] Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA
[3] RTI Int, Res Triangle Pk, NC USA
[4] NCI, Canc Therapy Evaluat Program, Washington, DC USA
[5] NIH, NCI, Bldg 10, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.10551
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10551
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program
    Kurmasheva, Raushan T.
    Sammons, Melissa
    Favours, Edward
    Wu, Jianwrong
    Kurmashev, Dias
    Cosmopoulos, Katherine
    Keilhack, Heike
    Klaus, Christine R.
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2017, 64 (03)
  • [2] Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies
    Qi, Lin
    Lindsay, Holly
    Kogiso, Mari
    Du, Yuchen
    Braun, Frank K.
    Zhang, Huiyuan
    Guo, Lei
    Zhao, Sibo
    Injac, Sarah G.
    Baxter, Patricia A.
    Su, Jack Mf
    Xiao, Sophie
    Erickson, Stephen W.
    Earley, Eric J.
    Teicher, Beverly
    Smith, Malcolm A.
    Li, Xiao-Nan
    LABORATORY INVESTIGATION, 2022, 102 (02) : 185 - 193
  • [3] Activity of the EZH2 inhibitor tazemetostat as a monotherapy and in combination with multiple myeloma therapies in preclinical models
    Drew, Allison E.
    Motwani, Vinny
    Campbell, John E.
    Tang, Cuyue
    Smith, Jesse J.
    Chesworth, Richard
    Copeland, Robert A.
    Raimondi, Alejandra
    Ribich, Scott
    CANCER RESEARCH, 2017, 77
  • [4] In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium
    Kurmasheva, Raushan T.
    Erickson, Stephen W.
    Earley, Eric
    Smith, Malcolm A.
    Houghton, Peter J.
    PEDIATRIC BLOOD & CANCER, 2021, 68 (02)
  • [5] Racial/ethnic differences of pediatric brain tumors in the development of orthotopic PDX models
    Qi, Lin
    Kogiso, Mari
    Du, Yuchen
    Huang, Yulun
    Zhang, Huiyuan
    Braun, Frank
    Lindsay, Holly
    Zhao, Sibo
    Injac, Sarah
    Perlaky, Lazlo
    Baxter, Patricia
    Teo, Wan-Yee
    Liu, Zhigang
    Zhao, Xiumei
    Zhang, Yujing
    Su, Jack M. F.
    Li, Xiao-Nan
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [6] Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib
    Cole, Kristina A.
    Houghton, Peter J.
    Kurmasheva, Raushan T.
    Gorlick, Richard
    Kolb, E. Anders
    Kang, Min
    Reynolds, C. Patrick
    Li, Xiao-Nan
    Lindsay, Holly
    Erickson, Stephen W.
    Guo, Yuelong
    Teicher, Beverly A.
    Smith, Malcolm A.
    Maris, John M.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [7] ORTHOTOPIC MODELS OF PEDIATRIC BRAIN TUMORS IN ZEBRAFISH
    Eden, Christopher
    Ju, Bensheng
    Phoenix, Timothy
    Nimmervoll, Birgit
    Tong, Yiai
    Ellison, David
    Lessman, Charles
    Taylor, Michael
    Gilbertson, Richard
    NEURO-ONCOLOGY, 2014, 16 : 141 - 141
  • [8] Orthotopic models of pediatric brain tumors in zebrafish
    C J Eden
    B Ju
    M Murugesan
    T N Phoenix
    B Nimmervoll
    Y Tong
    D W Ellison
    D Finkelstein
    K Wright
    N Boulos
    J Dapper
    R Thiruvenkatam
    C A Lessman
    M R Taylor
    R J Gilbertson
    Oncogene, 2015, 34 : 1736 - 1742
  • [9] Orthotopic models of pediatric brain tumors in zebrafish
    Eden, C. J.
    Ju, B.
    Murugesan, M.
    Phoenix, T. N.
    Nimmervoll, B.
    Tong, Y.
    Ellison, D. W.
    Finkelstein, D.
    Wright, K.
    Boulos, N.
    Dapper, J.
    Thiruvenkatam, R.
    Lessman, C. A.
    Taylor, M. R.
    Gilbertson, R. J.
    ONCOGENE, 2015, 34 (13) : 1736 - 1742
  • [10] A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma.
    Chi, Susan N.
    McCowage, Geoffrey Brian
    Hoffman, Lindsey
    Macy, Margaret
    Doleman, Susan
    Blakemore, Stephen J.
    Clawson, Alicia
    Daigle, Scott
    Tang, Jeanie
    Roche, Maria
    Ho, Peter T. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345